<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Hoyle, Brian</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Pagani, Olivia</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Comparison of Treatments for HR+ Early Breast Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-11</style></pages><abstract><style  face="normal" font="default" size="100%">This article presents the joint analysis of 2 randomized comparative trials coordinated by the International Breast Cancer Study Group, the Tamoxifen and Exemestane Trial [TEXT; NCT0006670] and the Suppression of Ovarian Function Trial [SOFT; NCT00066690]. The trials compared adjuvant exemestane plus ovarian function suppression versus tamoxifen plus ovarian function suppression in the treatment of premenopausal women with hormone receptor—positive (HR+) early breast cancer [Pagani O et al. J Clin Oncol 2014].</style></abstract><number><style face="normal" font="default" size="100%">14</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>